What is Rubicon Research Ltd (RUBICON) share price return in the past 10 years?

Data is not available for this company

What is the share price of Rubicon Research Ltd (RUBICON)?

Company share prices are keep on changing according to the market conditions. The current trading price of Rubicon Research Ltd (RUBICON) on 03-Jul-2026 16:59:59 at 16:59 is 1302.75.

What is the P/E ratio of Rubicon Research?

The latest standalone P/E ratio of Rubicon Research as of 03-Jul-2026 is 120.81.

What is the P/B ratio of Rubicon Research Ltd (RUBICON)?

The latest standalone P/B ratio of Rubicon Research Ltd (RUBICON) as of 03-Jul-2026 is 16.80.

What is the 52-week high and low of Rubicon Research Ltd (RUBICON)?

The 52-week high of Rubicon Research Ltd (RUBICON) is Rs. 1468.00 and the 52-week low is Rs. 571.00.

Rubicon Research Ltd (RUBICON) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Rubicon Research Ltd (RUBICON)
Brand: Rubicon Research

Key Metrics

Valuation Multiples

Market Cap

₹22,733 Cr.

Current Price

₹1,302.8

52-Week Low / High

₹571 / 1,468

TTM EPS

₹11.4

TTM Sales

₹1,306 Cr.

Book Value per Share

₹81.8

P/E Ratio

120.81

Industry PE

83.4

Price to Book (P/B)

16.80

Price to Sales (P/S)

17.41

EV/EBITDA

70.74

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

30.64%

Outperforms industry median

Return on Capital Employed (ROCE)

26.65%

Outperforms industry median

Return on Assets (ROA)

14.23%

Operating Profit Margin

25.2%

Net Profit Margin

15.6%

Gross Profit Margin

23.8%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

70.31%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

269.12%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

588.05%

Asset Quality

Promoter Holding

59.86%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹1,337 Cr.

Equity

₹16.5 Cr.

Face Value

₹1

All Time Low / High

₹571.00 / 1468.00

Rubicon Research stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Rubicon Research Ltd a good quality company?

Rubicon Research Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Rubicon Research Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Rubicon Research Ltd vs industry peers?

Rubicon Research Ltd revenue CAGR is 32.49%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Rubicon Research Ltd?

Promoters hold 59.86% of the Rubicon Research Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Rubicon Research Ltd over the last decade?

Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	7.4%	3%	1.6%	14.4%	28.2%	21.2%	4.7%	5.5%	7.9%	26.7%	-
Value Creation Index ⓘ	-0.3	-0.7	-0.9	0.3	1.5	0.9	-0.6	-0.5	-0.3	0.9	-
Growth Parameters ⓘ
Sales ⓘ	39.2	48.9	65.2	154	263	331	400	407	631	1,074	1,306
Sales YoY Gr.	-	24.8%	33.4%	136%	71%	26%	20.7%	1.9%	54.7%	70.3%	-
Adj EPS ⓘ	0.2	0.1	0.1	1.3	3.3	3.2	1.1	-0.3	0.9	10.5	11.4
YoY Gr.	-	-40%	-22.2%	1757.1%	154.6%	-3.9%	-65.4%	-123.6%	NA	1105.8%	-
BVPS (₹) ⓘ	4.8	12.9	12.7	14.3	22.8	26.3	27.4	28.2	29.7	41.6	81.8
Adj Net Profit ⓘ	0.9	1.2	0.9	18.4	50.4	48.3	16.8	-4	13.2	162	188
Cash Flow from Ops. ⓘ	7.6	-4.3	-15.4	-10.7	9.3	46.9	-37.1	-79	83.2	29.7	-
Debt/CF from Ops. ⓘ	3.8	-6.4	-1.9	-4.7	3.3	2	-4.6	-4	4.8	13.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	44.5%	32.5%	39%	70.3%
Adj EPS ⓘ	60.3%	26%	112.1%	1105.8%
BVPSⓘ	27.2%	12.8%	15%	40%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.9	1.1	0.5	9.7	18.1	12.6	4	-0.9	2.9	28.3	18.4
Op. Profit Mgn % ⓘ	25.1	17.8	8.2	23.2	34.1	33.6	10	10.2	11.6	25.2	23.2
Net Profit Mgn % ⓘ	2.3	2.5	1.4	12	19.2	14.6	4.2	-1	2.1	15.1	14.4
Debt to Equity ⓘ	0.6	0.2	0.2	0.3	0.1	0.2	0.4	0.7	0.9	0.6	0.1
Working Cap Days ⓘ	342	330	365	272	256	274	324	457	371	288	224
Cash Conv. Cycle ⓘ	131	151	178	122	139	164	176	264	194	134	111

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	39	49	65	154	263	331	400	407	631	1,074
Operating Expenses ⓘ +	29	40	60	119	173	220	360	366	557	804
Manufacturing Costs	3	3	4	7	26	63	110	93	79	109
Material Costs	5	9	14	35	45	55	103	125	214	308
Employee Cost	12	14	22	28	34	41	59	74	85	128
Other Costs ⓘ	10	14	20	49	68	61	88	74	179	259
Operating Profit ⓘ	10	9	5	35	90	111	40	41	73	270
Operating Profit Margin (%)	25.1%	17.7%	8.2%	22.8%	34.1%	33.6%	10.0%	10.2%	11.6%	25.1%
Other Income ⓘ +	0	1	4	6	18	11	17	28	26	20
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	3	3	2	3	6	9	9	19	31	34
Depreciation ⓘ	5	5	6	8	18	28	32	33	35	32
Profit Before Tax ⓘ	3	1	1	31	84	85	17	18	34	223
Tax ⓘ	2	0	0	9	25	32	0	6	10	56
Profit After Tax	1	1	1	22	59	53	17	13	24	168
PAT Margin (%)	2.3%	2.5%	1.5%	14.2%	22.5%	16.0%	4.2%	3.1%	3.9%	15.6%
Adjusted EPS (₹)	0.2	0.1	0.1	1.6	3.9	3.5	1.1	0.8	1.6	10.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	1.70%	1%	4.60%	2%	0.10%	0%

Valuation of Rubicon Research - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	48	181	179	201	347	399	416	429	452	642
Share Capital ⓘ	21	5	5	5	5	5	5	5	15	15
Reserves ⓘ	27	177	174	196	342	394	411	424	437	626
Debt +	24	23	26	42	24	82	155	293	357	355
Long Term Debt	9	12	12	28	4	38	63	97	93	64
Short Term Debt	15	11	14	14	19	43	91	196	264	290
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	4	10	19	22	32	58	74	98	184
Others Liabilities ⓘ	15	14	15	38	48	57	49	72	109	159
Total Liabilities ⓘ	92	223	230	300	442	570	678	868	1,016	1,339
Fixed Assets
Net Fixed Assets ⓘ +	37	41	44	68	151	177	181	183	232	259
Gross Block	65	75	82	111	211	265	299	334	410	461
Accumulated Depreciation	28	34	38	43	60	88	119	152	178	202
CWIP ⓘ	15	16	25	57	2	4	3	25	10	6
Investments ⓘ	0	115	78	18	35	32	19	26	34	36
Inventories	2	7	14	19	38	57	58	99	181	258
Trade Receivables	19	24	37	84	140	154	234	350	252	501
Cash Equivalents	1	2	2	9	33	79	44	46	48	37
Others Assets ⓘ	18	18	30	45	42	67	142	139	259	241
Total Assets ⓘ	92	223	230	300	442	570	678	868	1,016	1,339

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	-4	-15	-11	9	47	-37	-79	83	30
PBT ⓘ	3	1	1	31	84	85	17	18	34	223
Adjustment ⓘ	6	5	10	16	20	26	25	40	52	68
Changes in Working Capital ⓘ	1	-10	-26	-57	-68	-31	-71	-136	13	-235
Tax Paid ⓘ	-2	-1	-0	-0	-27	-33	-8	-0	-16	-27
Cash Flow From Investing Activity ⓘ +	-8	-122	17	1	-85	-32	-86	-34	-130	-10
Capex	-8	-7	-23	-64	0	0	0	-37	-56	-70
Net Investments	0	0	-3	-4	-14	3	0	0	-11	-4
Others ⓘ	-0	-114	42	70	-72	-35	-86	3	-63	64
Cash Flow From Financing Activity ⓘ +	-0	127	-3	16	76	52	65	124	46	-34
Net Proceeds from Shares ⓘ	0	147	0	0	0	0	0	0	0	8
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	28	0	44	10	-30
Interest Paid ⓘ	-3	-3	-2	-2	-6	-1	0	-18	-28	-33
Dividend Paid ⓘ	0	0	0	0	0	0	-1	-0	-0	-0
Others ⓘ	2	-17	-1	19	82	25	66	98	64	21
Net Cash Flow ⓘ	-1	1	-1	6	-0	67	-58	11	-1	-14

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	3.16	1.15	0.53	11.48	21.55	14.19	4.09	3.01	5.53	30.64
ROCE (%)	7.44	3.02	1.62	14.43	28.21	21.21	4.71	5.45	7.91	26.65
Asset Turnover Ratio	0.45	0.31	0.29	0.58	0.71	0.66	0.64	0.53	0.67	0.91
PAT to CFO Conversion(x)	8	-4	-15	-0.5	0.15	0.89	-2.18	-6.08	3.46	0.18
Working Capital Days
Receivable Days	166.50	161.60	172.40	144.40	155.80	161.90	176.80	261.60	174.40	128.10
Inventory Days	13.90	34.90	60.10	39.60	39.60	52	52.10	70	81.10	74.70
Payable Days	247.90	167.80	189.60	153.80	168.10	180.10	160	193.60	146.50	167.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Rubicon Research Ltd FAQs

The current trading price of Rubicon Research on 03-Jul-2026 16:59 is ₹1,302.8.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Jul-2026 the market cap of Rubicon Research stood at ₹22,732.7 Cr

The latest P/E ratio of Rubicon Research as of 02-Jul-2026 is 120.8.

The latest P/B ratio of Rubicon Research as of 02-Jul-2026 is 16.80.

The 52-week high of Rubicon Research is ₹1,468 and the 52-week low is ₹571.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Rubicon Research is ₹1,306 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Rubicon Research Ltd is a average quality company.

The key valuation ratios of Rubicon Research Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Rubicon Research Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Rubicon Research Ltd

Rubicon Research was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name ‘Rubicon Consultants Private Limited’, pursuant to a certificate of incorporation issued by the RoC.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and the company), it is the only Indian pharmaceutical player with a complete focus on regulated markets.

The company’s multi-disciplinary, data-driven, and return on investment (ROI) centric product selection framework is geared towards identifying sustainable opportunities for new product development. It identifies and pursues such opportunities in a manner that provides it a competitive advantage by leveraging its development, manufacturing, and commercialization capabilities to create and grow its share of the market.

Business area of the company

Rubicon Research, incorporated in 1999, is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. Further, the company has robust sales and distribution capabilities in the US.

Products of the company

Metoprolol Tartrate
Cyclobenzaprine Hydrochloride
Carbidopa-Levodopa
Diclofenac Potassium
Baclofen
Rabeprazole Sodium
Lidocaine Hydrochloride
Tramadol Hydrochloride

History and milestones

2007: Received investment from Kotak India Venture Fund - I, Kotak India Venture Limited and Kotak Employees Investment Trust.
2011: Commencement of manufacturing of certain special drugs in Ambernath Manufacturing Facility.
2011: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility for tablet manufacturing and secondary packaging by Medicines and Healthcare Products Regulatory Agency, United Kingdom.
2013: Receipt of GMP clearance approval for Ambernath Manufacturing Facility from Department of Health and Ageing Therapeutic Goods Administration, Australian Government.
2014: Receipt of approval for its product i.e., ‘metoprolol tartrate tablets’ from the Food & Drug Administration, United State of America.
2016: Acquisition of majority stake by ECP III Pte Ltd.
2017: Receipt of certificate of GMP compliance for Ambernath Manufacturing Facility from the Ministerio De Sandidad, Servicios Sociales E Igualdad, Spain.
2019: Acquisition of majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd.
2019: Acquisition of Impopharma Canada Limited by Rubicon Research Canada Limited
2021: Acquired the business of Meditab Specialities Limited on a slump sale basis.
2022: Set up own sales and marketing front end in US via its Material Subsidiary.
2023: Receipt of certificate of GMP compliance for Satara Manufacturing Facility of non-sterile liquid drug manufacturer and pre-approval coverage provided for non-sterile liquid product by US FDA.
2024: Acquisition of Validus Pharmaceuticals LLC.
2024: ANDA pre-approval drug inspection of nasal spray block at Ambernath Manufacturing Facility by USFDA.
2024: Receipt of supplement approval for Thane R&D Facility as a testing site of drug substance - lead test from USFDA.
2024: Received USFDA establishment inspection report for Ambernath Manufacturing Facility.
2024: Commencement of manufacturing of nasal products at Ambernath Manufacturing Facility.
2025: Received new drug application approval from USFDA for Lopressor (Metoprolol Tartrate) oral solution.
2025: Received USFDA establishment inspection report for Thane R&D Facility.
2025: Acquisition of Pithampur Manufacturing Facility from Alkem Laboratories Limited.
2025: Acquisition of AIM RX 3PL LLC.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Rubicon Research Ltd (RUBICON)

Rubicon Research Ltd (RUBICON)

Rubicon Research stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Rubicon Research - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Rubicon Research Ltd FAQs

What is the share price of Rubicon Research?

What is the market cap of Rubicon Research?

What is the P/E ratio of Rubicon Research?

What is the P/B ratio of Rubicon Research?

What is the 52-week high and low of Rubicon Research?

What is the TTM revenue of Rubicon Research?

Is Rubicon Research Ltd a good quality company?

Is Rubicon Research Ltd undervalued or overvalued?

Is Rubicon Research Ltd a good buy now?

About Rubicon Research Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.